Sacrix New 3D Porous Sacroiliac Joint (SIJ) Threaded Implant For Percutaneous Minimally Invasive SI Joint Fusion
the patent includes a device claim of our threaded implant with the fusion channel; also an embodiment with a 3D porous structure
MALDEN, Mass. (PRWEB) 18 Septembrie, 2021
Vito Lore, the VP of innovations at KICVentures Group, said “the patent includes a device claim of our threaded implant with the fusion channel; also an embodiment with a 3D porous structure”.
“Clinically the 3D porous structure is expected to enhance the threaded implant’s performance in fixating the sacroiliac joint and accelerating fusion” said Co-Inventor Dr Kingsley R. Chin, a Professor and Board-Certified Orthopedic Spine Surgeon and acting CEO of Sacrix LLC.
Sacrix LLC has pioneered a new percutaneous lateral-oblique sacroiliac joint fusion technique that will now make it even easier with the self-tapping, self-drilling and self-harvesting features of this patented 3D porous threaded implant.
Sacrix LLC thanks the dedicated team of engineers, Oscar Herrera, Raul Gawande, Darryl Campbell-Spaulding, and industrial designer Josh Finkel as they worked with focus and urgency to bring this landmark technology to our physicians and patients.
About Sacrix LLC
Sacrix LLC is a KICVentures Group portfolio company focused on revolutionary percutaneous lateral-oblique sacroiliac joint fusion technologies for the treatment of sacroiliac dysfunction and sacroiliitis. Sacrix developed its patented Sacrofuse threaded implant to be inserted percutaneously and received FDA clearance in 2015. The Gen1 Sacrofuse implant was compared head-to-head with market leader SI bone (SIBN) and found to have a 400% increase in pull out strength. Sacrix has trained over 165 interventional pain physicians to perform its revolutionary percutaneous lateral-oblique sacroiliac joint fusion technique safely and effectively through a 1.5 cm incision minimally invasively in outpatient ambulatory surgery centers.
http://www.MySacrix.com
Despre KICVentures Group
Înființată în 2000, ne face cel mai experimentat holding de investiții în domeniul sănătății, cu cel mai mare portofoliu de tehnologii de dispozitive medicale axate pe soluții pentru intervenții chirurgicale mai puțin invazive ale coloanei vertebrale. Strategia noastră de investiții este să achiziționăm sau să inventăm tehnologii disruptive folosind propriul nostru capital sau parteneriat cu investitori privați. Acest lucru ne permite libertatea de a lua decizii rapide și agile, cum ar fi atunci când am achiziționat AxioMed Viscoelastic Disc Technologies, în timp ce alte firme au investit în distanțiere articulate cu bile și soclu.
http://www.KICVentures.com
Trimiteți articolul pe social media sau pe e-mail: